CAMBRIDGE, Mass.--(BUSINESS WIRE)--Metamark Genetics, Inc., a privately held oncology molecular diagnostics company, today announced the successful completion of proof-of-concept (POC) for its biomarker prognostic test for prostate cancer. The Metamark test is being developed to help physicians more accurately determine whether a male’s prostate cancer is slow-growing or aggressive, based on tumor tissue biopsy.
